<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28643425</article-id><article-id pub-id-type="pmc">5763397</article-id><article-id pub-id-type="doi">10.1111/dom.13043</article-id><article-id pub-id-type="publisher-id">DOM13043</article-id><article-categories><subj-group subj-group-type="overline"><subject>Brief Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Brief Reports</subject></subj-group></article-categories><title-group><article-title>Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the <styled-content style="fixed-case">DUAL V</styled-content> randomized trial</article-title></title-group><contrib-group><contrib id="dom13043-cr-0001" contrib-type="author" corresp="yes"><name><surname>Lingvay</surname><given-names>Ildiko</given-names></name><degrees>MD, MPH, MSCS</degrees><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7006-7401</contrib-id><address><email>ildiko.lingvay@utsouthwestern.edu</email></address><xref ref-type="aff" rid="dom13043-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom13043-cr-0002" contrib-type="author"><name><surname>Harris</surname><given-names>Stewart</given-names></name><degrees>MD, CM, MPH</degrees><xref ref-type="aff" rid="dom13043-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom13043-cr-0003" contrib-type="author"><name><surname>Jaeckel</surname><given-names>Elmar</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom13043-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom13043-cr-0004" contrib-type="author"><name><surname>Chandarana</surname><given-names>Keval</given-names></name><degrees>MBBS, PhD, BSc</degrees><xref ref-type="aff" rid="dom13043-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom13043-cr-0005" contrib-type="author"><name><surname>Ranthe</surname><given-names>Mattis F.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="dom13043-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="dom13043-cr-0006" contrib-type="author"><name><surname>J&#x000f3;dar</surname><given-names>Esteban</given-names></name><degrees>MA, PhD</degrees><xref ref-type="aff" rid="dom13043-aff-0006">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="dom13043-aff-0001" content-type="private-address">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Internal Medicine/Endocrinology and Clinical Sciences</named-content>
<institution>UT Southwestern Medical Center</institution>
<named-content content-type="city">Dallas</named-content>
<named-content content-type="country-part">Texas</named-content>
<country>USA</country>
</aff><aff id="dom13043-aff-0002" content-type="private-address">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Centre for Studies in Family Medicine</named-content>
<institution>University of Western Ontario</institution>
<named-content content-type="city">London</named-content>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><aff id="dom13043-aff-0003" content-type="private-address">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Gastroenterology, Hepatology and Endocrinology</named-content>
<institution>Hannover Medical School</institution>
<named-content content-type="city">Hannover</named-content>
<country country="DE">Germany</country>
</aff><aff id="dom13043-aff-0004" content-type="private-address">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Medical Affairs</named-content>
<institution>Novo Nordisk A/S</institution>
<named-content content-type="city">S&#x000f8;borg</named-content>
<country country="DK">Denmark</country>
</aff><aff id="dom13043-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Medical and Science</named-content>
<institution>Novo Nordisk A/S</institution>
<named-content content-type="city">S&#x000f8;borg</named-content>
<country country="ES">Denmark</country>
</aff><aff id="dom13043-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Department of Endocrinology and Clinical Nutrition, University Hospital Quiron Salud Madrid</named-content>
<institution>Universidad Europea de Madrid</institution>
<named-content content-type="city">Madrid</named-content>
<country country="ES">Spain</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Ildiko Lingvay, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, USA 75390&#x02010;9320. Email: <email>ildiko.lingvay@utsouthwestern.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2018</year></pub-date><volume>20</volume><issue>1</issue><issue-id pub-id-type="doi">10.1111/dom.2018.20.issue-1</issue-id><fpage>200</fpage><lpage>205</lpage><history><date date-type="received"><day>15</day><month>3</month><year>2017</year></date><date date-type="rev-recd"><day>06</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>19</day><month>6</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>Diabetes, Obesity and Metabolism</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-20-200.pdf"/><abstract><p>This study assessed the efficacy of insulin degludec/liraglutide (<styled-content style="fixed-case">IDegLira</styled-content>) vs insulin glargine <styled-content style="fixed-case">U</styled-content>100 (<styled-content style="fixed-case">IG</styled-content>lar) across categories of baseline glycated haemoglobin (<styled-content style="fixed-case">HbA1c</styled-content>; &#x02264;7.5%, &#x0003e;7.5% to &#x02264;8.5% and &#x0003e;8.5%), body mass index (<styled-content style="fixed-case">BMI</styled-content>; &#x0003c;30, &#x02265;30 to &#x0003c;35 and &#x02265;35&#x02009;kg/m<sup>2</sup>) and fasting plasma glucose (<styled-content style="fixed-case">FPG</styled-content>; &#x0003c;7.2 and &#x02265;7.2&#x02009;mmol/L) in patients with type 2 diabetes (<styled-content style="fixed-case">T2D</styled-content>) uncontrolled on basal insulin, using <styled-content style="italic-in-any-context">post hoc</styled-content> analyses of the <styled-content style="fixed-case">DUAL V</styled-content> 26&#x02010;week trial. With <styled-content style="fixed-case">IDegLira</styled-content>, mean <styled-content style="fixed-case">HbA1c</styled-content> was reduced across all baseline <styled-content style="fixed-case">HbA1c</styled-content> (1.0%&#x02010;2.5%), <styled-content style="fixed-case">FPG</styled-content> (1.5%&#x02010;1.9%) and <styled-content style="fixed-case">BMI</styled-content> categories (1.8%&#x02010;1.9%), with significantly greater reductions compared with <styled-content style="fixed-case">IGlar</styled-content> U100. For all <styled-content style="fixed-case">HbA1c</styled-content>, <styled-content style="fixed-case">FPG</styled-content> and <styled-content style="fixed-case">BMI</styled-content> categories, <styled-content style="fixed-case">IDegLira</styled-content> resulted in weight loss and <styled-content style="fixed-case">IGlar</styled-content> U100 in weight gain; hypoglycaemia rates were lower for <styled-content style="fixed-case">IDegLira</styled-content> vs <styled-content style="fixed-case">IGlar</styled-content> U100. More patients achieved <styled-content style="fixed-case">HbA1c</styled-content> &#x0003c;7% with <styled-content style="fixed-case">IDegLira</styled-content> than <styled-content style="fixed-case">IGlar</styled-content> U100 across all <styled-content style="fixed-case">HbA1c</styled-content> (59%&#x02010;87% vs 31%&#x02010;66%), <styled-content style="fixed-case">FPG</styled-content> (71%&#x02010;74% vs 40%&#x02010;51%) and BMI categories (71%&#x02010;73% vs 40%&#x02010;54%). <styled-content style="fixed-case">IDegLira</styled-content> improved glycaemic control and induced weight loss in patients with <styled-content style="fixed-case">T2D</styled-content> previously uncontrolled on basal insulin, across the categories of baseline <styled-content style="fixed-case">HbA1c</styled-content>, <styled-content style="fixed-case">FPG</styled-content> or <styled-content style="fixed-case">BMI</styled-content> that were tested.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom13043-kwd-0001">body mass index</kwd><kwd id="dom13043-kwd-0002">clinical trial</kwd><kwd id="dom13043-kwd-0003"><styled-content style="fixed-case">IDegLira</styled-content></kwd><kwd id="dom13043-kwd-0004">insulin therapy</kwd><kwd id="dom13043-kwd-0005">type 2 diabetes</kwd></kwd-group><funding-group><award-group><funding-source>Novo Nordisk</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="0"/><page-count count="1"/><word-count count="3445"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom13043</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.8 mode:remove_FC converted:11.01.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dom13043-cit-1001">
<string-name>
<surname>Lingvay</surname>
<given-names>I.</given-names>
</string-name>, <string-name>
<surname>Harris</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Jaeckel</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Chandarana</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Ranthe</surname>
<given-names>M.F.</given-names>
</string-name>, <string-name>
<surname>J&#x000f3;dar</surname>
<given-names>E.</given-names>
</string-name>
<article-title>Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial</article-title>. <source>Diabetes Obes Metab</source>. <year>2018</year>;<volume>20</volume>:<fpage>200</fpage>&#x02013;<lpage>205</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/dom.13043">https://doi.org/10.1111/dom.13043</ext-link>
<pub-id pub-id-type="pmid">28643425</pub-id></mixed-citation>
</p><fn-group id="dom13043-ntgp-0001a"><fn id="dom13043-note-0001a"><p>
<bold>Funding information</bold> This study was funded by Novo Nordisk. Novo Nordisk was involved in the trial design and protocol development, provided logistical support, and obtained the data, which were evaluated jointly by the authors and the sponsor. The writing of this paper was supported by Novo Nordisk A/S</p></fn></fn-group></notes></front><body><sec id="dom13043-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Because of the progressive nature of type 2 diabetes (T2D), achieving and maintaining glycaemic control and selecting the optimum therapy for an individual patient can be challenging.<xref rid="dom13043-bib-0001" ref-type="ref">1</xref>, <xref rid="dom13043-bib-0002" ref-type="ref">2</xref>, <xref rid="dom13043-bib-0003" ref-type="ref">3</xref> Characteristics such as glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), and body mass index (BMI) are often taken into consideration when individualizing treatment; therefore, information on how specific therapies perform with regard to such characteristics is essential in order to individualize diabetes treatment options.</p><p>The DUAL clinical trial programme investigated the efficacy and safety of the fixed&#x02010;ratio combination insulin degludec/liraglutide (IDegLira) in various T2D populations, including insulin&#x02010;na&#x000ef;ve participants uncontrolled on oral antidiabetic drugs (OADs; DUAL I, IV and VI),<xref rid="dom13043-bib-0004" ref-type="ref">4</xref>, <xref rid="dom13043-bib-0005" ref-type="ref">5</xref>, <xref rid="dom13043-bib-0006" ref-type="ref">6</xref>, <xref rid="dom13043-bib-0007" ref-type="ref">7</xref> on glucagon&#x02010;like peptide&#x02010;1 receptor agonists (GLP&#x02010;1RAs) and OADs (DUAL III),<xref rid="dom13043-bib-0008" ref-type="ref">8</xref> or on basal insulin and OADs (DUAL II and V).<xref rid="dom13043-bib-0009" ref-type="ref">9</xref>, <xref rid="dom13043-bib-0010" ref-type="ref">10</xref>
<italic>Post hoc</italic> analyses of DUAL I and II indicated that IDegLira was efficacious regardless of HbA1c or BMI at baseline.<xref rid="dom13043-bib-0005" ref-type="ref">5</xref>, <xref rid="dom13043-bib-0011" ref-type="ref">11</xref>
</p><p>To help identify which patient populations would benefit most from IDegLira treatment, we report <italic>post hoc</italic> analyses of DUAL V, evaluating whether glycaemic control, weight and hypoglycaemia benefits associated with IDegLira were consistent across patient subgroups.</p></sec><sec id="dom13043-sec-0002"><label>2</label><title>MATERIALS AND METHODS</title><p>The detailed trial design and methods have been reported previously.<xref rid="dom13043-bib-0010" ref-type="ref">10</xref> The trial was approved by institutional review boards, and was registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> (NCT01952145). DUAL V was a phase III, multinational, multicentre, randomized, 26&#x02010;week clinical trial conducted in patients with T2D who were uncontrolled on IGlar U100 (20&#x02010;50&#x02009;units) in combination with metformin. A total of 557 patients were randomized 1:1 to either convert from IGlar U100 to IDegLira or continue uptitration of IGlar U100.<xref rid="dom13043-bib-0010" ref-type="ref">10</xref> The IDegLira starting dose was 16&#x02009;dose steps (16&#x02009;units IDeg/0.6&#x02009;mg liraglutide) and maximum dose was 50&#x02009;dose steps (50&#x02009;units IDeg/1.8&#x02009;mg liraglutide). IGlar U100 treatment was started at pre&#x02010;trial dose, with no maximum dose. Both treatments were dosed once daily and titrated to a FPG target of 4 to 5&#x02009;mmol/L (to convert to mg/dL multiply by 18.02).<xref rid="dom13043-bib-0010" ref-type="ref">10</xref>
</p><p>For the present <italic>post hoc</italic> analyses, patients were grouped according to baseline HbA1c (&#x02264;7.5%, &#x0003e;7.5% to &#x02264;8.5% and &#x0003e;8.5%), FPG (&#x0003c;7.2 and &#x02265;7.2&#x02009;mmol/L)<xref rid="dom13043-bib-0012" ref-type="ref">12</xref> and BMI (&#x0003c;30, &#x02265;30 to &#x0003c;35 and &#x02265;35&#x02009;kg/m<sup>2</sup>).</p><p>The following endpoints were analysed for each category at end&#x02010;of&#x02010;trial (EOT): change in HbA1c; change in body weight; number of confirmed hypoglycaemic episodes during the trial; patients reaching the European Association for the Study of Diabetes/American Diabetes Association target of HbA1c &#x0003c;7%<xref rid="dom13043-bib-0012" ref-type="ref">12</xref> and composite endpoints (HbA1c &#x0003c;7% without hypoglycaemia [in the last 12&#x02009;weeks], and HbA1c &#x0003c;7% without hypoglycaemia [in the last 12&#x02009;weeks] and without weight gain); and daily insulin dose. Confirmed hypoglycaemia was defined as plasma glucose &#x0003c;3.1&#x02009;mmol/L or severe hypoglycaemia (unable to self&#x02010;treat). Details of statisistical analyses are provided in Appendix S1.</p></sec><sec id="dom13043-sec-0003"><label>3</label><title>RESULTS</title><p>The distribution of patients across baseline HbA1c, BMI and FPG categories is shown in Table S1, Appendix S1.</p><sec id="dom13043-sec-0004"><label>3.1</label><title>Efficacy of <styled-content style="fixed-case">IDegLira</styled-content> by baseline <styled-content style="fixed-case">HbA1c</styled-content>
</title><p>With IDegLira, the mean EOT HbA1c for all baseline HbA1c categories was &#x0003c;7% (Figure <xref rid="dom13043-fig-0001" ref-type="fig">1</xref>A), with greater HbA1c reductions achieved with increasing baseline HbA1c. IDegLira resulted in significantly greater HbA1c reductions than IGlar U100 across all baseline HbA1c categories (Figure <xref rid="dom13043-fig-0001" ref-type="fig">1</xref>A; <italic>P</italic>&#x02009;&#x0003c;&#x02009;.0001 for all categories). The estimated treatment difference (ETD) between baseline categories was not significantly different (interaction analysis, <italic>P</italic>&#x02009;=&#x02009;.6406), indicating a similar benefit of IDegLira vs IGlar U100 across categories.</p><fig fig-type="Figure" xml:lang="en" id="dom13043-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Change in <styled-content style="fixed-case">HbA1c</styled-content> and body weight with <styled-content style="fixed-case">IDegLira</styled-content> across categories of baseline <styled-content style="fixed-case">HbA1c</styled-content> (<styled-content style="fixed-case">A</styled-content> and <styled-content style="fixed-case">B</styled-content>), <styled-content style="fixed-case">FPG</styled-content> (<styled-content style="fixed-case">C</styled-content> and <styled-content style="fixed-case">D</styled-content>) and <styled-content style="fixed-case">BMI</styled-content> (<styled-content style="fixed-case">E</styled-content> and <styled-content style="fixed-case">F</styled-content>). Data based on the full analysis set, with missing data imputed by last observation carried forward. Data are mean values with <styled-content style="fixed-case">ETD</styled-content> (95% confidence interval) based on analysis of covariance. For (<styled-content style="fixed-case">A</styled-content>), (<styled-content style="fixed-case">C</styled-content>) and (<styled-content style="fixed-case">E</styled-content>) dotted line represents <styled-content style="fixed-case">A</styled-content>merican <styled-content style="fixed-case">D</styled-content>iabetes <styled-content style="fixed-case">A</styled-content>ssociation <styled-content style="fixed-case">HbA1c</styled-content> target &#x0003c;7.0%</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-20-200-g001"/></fig><p>For all baseline HbA1c categories, IDegLira was associated with a mean weight loss and IGlar U100 with a mean weight gain (Figure <xref rid="dom13043-fig-0001" ref-type="fig">1</xref>B), with an increasing weight difference with higher baseline HbA1c (interaction analyses <italic>P</italic>&#x02009;&#x0003c;&#x02009;.0001).</p><p>Confirmed hypoglycaemia rates were lower for IDegLira (1.5&#x02010;3.1 episodes/per patient&#x02010;year exposure [PYE]) compared with IGlar U100 (2.7&#x02010;6.2 episodes/PYE) for all baseline HbA1c categories (Figure S1A, Appendix S1).</p><p>In addition, a greater proportion of patients treated with IDegLira vs IGlar U100 achieved HbA1c &#x0003c;7%, HbA1c &#x0003c;7% without hypoglycaemia, and HbA1c &#x0003c;7% without hypoglycaemia and no weight gain (Figure <xref rid="dom13043-fig-0002" ref-type="fig">2</xref>A). The odds ratios (OR) for all composite endpoints were similar across baseline HbA1c categories, indicating a similar beneficial effect of IDegLira vs IGlar U100 (results of interaction analyses, <italic>P</italic>&#x02009;=&#x02009;.8841, <italic>P</italic>&#x02009;=&#x02009;.6587 and <italic>P</italic>&#x02009;=&#x02009;.2784 for HbA1c &#x0003c;7%, HbA1c &#x0003c;7% without hypoglycaemia, and HbA1c &#x0003c;7% without hypoglycaemia and no weight gain, respectively).</p><fig fig-type="Figure" xml:lang="en" id="dom13043-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>
<styled-content style="fixed-case">HbA1c</styled-content> responders with <styled-content style="fixed-case">IDegLira</styled-content> vs <styled-content style="fixed-case">IGlar U</styled-content>100 in patients stratified according to baseline <styled-content style="fixed-case">A</styled-content>, <styled-content style="fixed-case">HbA1c</styled-content>; <styled-content style="fixed-case">B</styled-content>, <styled-content style="fixed-case">FPG</styled-content> and <styled-content style="fixed-case">C</styled-content>, <styled-content style="fixed-case">BMI</styled-content>. Data are percentage of patients reaching <styled-content style="fixed-case">HbA1c</styled-content> target &#x0003c;7% and composite endpoints at <styled-content style="fixed-case">EOT</styled-content>, based on the full analysis set with missing data imputed by last observation carried forward. Hypoglycaemic events defined as patient unable to self&#x02010;treat and/or plasma glucose &#x0003c;3.1&#x02009;mmol/L occurring during the last 12&#x02009;weeks of treatment</p></caption><graphic id="nlm-graphic-3" xlink:href="DOM-20-200-g002"/></fig><p>The mean daily EOT insulin dose was similar for IDegLira (40&#x02010;42&#x02009;units) for all baseline HbA1c categories and significantly lower than IGlar U100 (60&#x02010;73&#x02009;units; Figure S1B, Appendix S1). Across baseline HbA1c categories, a similar proportion of patients reached the maximum IDegLira dose of 50&#x02009;units after 26&#x02009;weeks: HbA1c &#x0003e;7.5%, 42.9%; HbA1c &#x0003e;7.5% to &#x02264;8.5%, 44.3%.</p></sec><sec id="dom13043-sec-0005"><label>3.2</label><title>Efficacy of <styled-content style="fixed-case">IDegLira</styled-content> by baseline <styled-content style="fixed-case">FPG</styled-content>
</title><p>IDegLira treatment resulted in similar, significantly greater, HbA1c reductions for both baseline FPG categories than for IGlar U100 (Figure <xref rid="dom13043-fig-0001" ref-type="fig">1</xref>C, both <italic>P</italic>&#x02009;&#x0003c;&#x02009;.0001; results of interaction analysis, <italic>P</italic>&#x02009;=&#x02009;.1764).</p><p>IDegLira was associated with weight loss and IGlar U100 with weight gain for both baseline FPG categories (Figure <xref rid="dom13043-fig-0001" ref-type="fig">1</xref>D), with a similar ETD for both categories (results of interaction analysis, <italic>P</italic>&#x02009;=&#x02009;.5257).</p><p>Hypoglycaemia rates were numerically lower for IDegLira vs IGlar U100 for both baseline FPG categories, but this difference was only significant (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.0001) for baseline FPG &#x02265;7.2&#x02009;mmol/L (Figure S2A, Appendix S1).</p><p>In both FPG categories, more IDegLira&#x02010;treated patients than IGlar U100&#x02010;treated patients achieved HbA1c &#x0003c;7%, HbA1c &#x0003c;7% without hypoglycaemia, and HbA1c &#x0003c;7% without hypoglycaemia and no weight gain (Figure <xref rid="dom13043-fig-0002" ref-type="fig">2</xref>B).</p><p>At EOT, the mean daily insulin dose was significantly greater (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.0001) for IGlar U100 (55&#x02010;72&#x02009;units) vs IDegLira (38&#x02010;42&#x02009;units) for both baseline FPG categories (Figure S2B, Appendix S1).</p></sec><sec id="dom13043-sec-0006"><label>3.3</label><title>Efficacy of <styled-content style="fixed-case">IDegLira</styled-content> by baseline <styled-content style="fixed-case">BMI</styled-content>
</title><p>Similar HbA1c reductions were observed with IDegLira across baseline BMI categories (all to &#x0003c;7%), and all were significantly greater vs IGlar U100 (Figure <xref rid="dom13043-fig-0001" ref-type="fig">1</xref>E). The interaction analysis indicated a similar beneficial effect of IDegLira vs IGlar U100 across BMI categories (<italic>P</italic>&#x02009;=&#x02009;.7873).</p><p>For all baseline BMI categories, IDegLira was associated with weight loss and IGlar U100 with weight gain (Figure <xref rid="dom13043-fig-0001" ref-type="fig">1</xref>F), with similar ETDs across categories (results of interaction analyses <italic>P</italic>&#x02009;=&#x02009;.5350).</p><p>The rates of hypoglycaemia with IDegLira were low for baseline BMI categories (1.5&#x02010;3.2 episodes/PYE) and were consistently lower vs IGlar U100 (Figure S3A, Appendix S1). The highest hypoglycaemia rate was seen in patients with a BMI &#x0003c;30&#x02009;kg/m<sup>2</sup>.</p><p>For each baseline BMI category, the proportion of patients achieving responder and composite endpoints was greater with IDegLira vs IGlar U100 (Figure <xref rid="dom13043-fig-0002" ref-type="fig">2</xref>C); the difference in ORs was significant (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.01) for all comparisons except the composite of HbA1c &#x0003c;7% without hypoglycaemia in the baseline BMI &#x02265;35&#x02009;kg/m<sup>2</sup> category (<italic>P</italic>&#x02009;=&#x02009;.0509). For HbA1c &#x0003c;7%, HbA1c &#x0003c;7% without hypoglycaemia, and HbA1c &#x0003c;7% without hypoglycaemia and no weight gain, the OR was similar (results of interaction analyses, <italic>P</italic>&#x02009;=&#x02009;.6776, <italic>P</italic>&#x02009;=&#x02009;.2195 and <italic>P</italic>&#x02009;=&#x02009;.7346, respectively), indicating a similar effect of IDegLira vs IGlar U100 across all baseline BMI categories.</p><p>The EOT IDegLira dose ranged from 37 to 45&#x02009;dose steps, with a higher proportion of patients in the higher baseline BMI categories reaching the maximum dose of 50&#x02009;dose steps after 26&#x02009;weeks: &#x0003c;30&#x02009;kg/m<sup>2</sup>, 25.3%; &#x02265;30 to &#x0003c;35&#x02009;kg/m<sup>2</sup>, 41.8%; &#x02265;35&#x02009;kg/m<sup>2</sup>, 62.3%. Daily insulin dose was significantly higher (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.0001) for IGlar U100 (56&#x02010;73&#x02009;units) vs IDegLira for all baseline BMI categories (Figure S3B, Appendix S1).</p></sec></sec><sec id="dom13043-sec-0007"><label>4</label><title>DISCUSSION</title><p>The DUAL V study showed that IDegLira is an efficacious alternative to uptitration of IGlar U100, providing glycaemic control with a low rate of hypoglycaemia and without weight gain.<xref rid="dom13043-bib-0010" ref-type="ref">10</xref> These <italic>post hoc</italic> analyses further demonstrate the applicability of IDegLira in different patient populations according to baseline HbA1c, FPG and BMI, helping predict the treatment response for patients in clinical practice and highlighting the efficacy and safety of IDegLira in patients at higher risk.</p><p>IDegLira effectively reduced HbA1c to similar levels for all baseline HbA1c categories, with greater overall reductions in HbA1c for patients with higher HbA1c levels at baseline. Interestingly, the daily insulin dose at EOT was similar for IDegLira across all baseline HbA1c categories (40&#x02010;42&#x02009;units), but increased according to baseline HbA1c for IGlar U100 (60&#x02010;73&#x02009;units). A similar trend was also observed in analyses by baseline FPG, suggesting that in patients with T2D uncontrolled on basal insulin, it may be more appropriate to use a therapy that addresses postprandial glucose, and/or suppresses glucagon, than continuing to increase basal insulin dose.<xref rid="dom13043-bib-0013" ref-type="ref">13</xref> These results also underline the complementary effects of using the combination product IDegLira, even in patients with high HbA1c and FPG.</p><p>Across baseline BMI categories, IDegLira resulted in similar HbA1c reductions, all resulting in an EOT HbA1c of 6.6%. This consistent benefit of IDegLira contrasts with, and could potentially challenge, some clinical guidelines that suggest the benefits of GLP&#x02010;1RAs are only realized in patients with a BMI &#x02265;35&#x02009;kg/m<sup>2</sup> or significant obesity&#x02010;related comorbidities.<xref rid="dom13043-bib-0014" ref-type="ref">14</xref>
</p><p>The proportion of patients achieving HbA1c levels &#x0003c;7% and the composite endpoints was consistently higher for IDegLira vs IGlar U100 across all baseline HbA1c, FPG and BMI categories. As expected, the proportion of responders decreased with both treatments, with increasing baseline HbA1c; this pattern was not evident for the analyses of FPG and BMI. The proportion of patients achieving HbA1c &#x0003c;7% without hypoglycaemia and with no weight gain increased with baseline BMI for both IDegLira and IGlar U100, although the proportions achieving the target was significantly higher with IDegLira vs IGlar U100, possibly resulting from increased insulin resistance with increasing BMI. Additionally, mean daily insulin dose for the &#x02265;30 to &#x0003c;35 and &#x02265;35&#x02009;kg/m<sup>2</sup> baseline categories increased from baseline &#x0003e;2&#x02010;fold by EOT, suggesting that, while some patients with a high BMI can achieve major improvements in HbA1c with large increases in daily dose of basal insulin, this may come at the cost of further weight gain and hypoglycaemia, which could be mitigated by switching patients to IDegLira.</p><p>Hypoglycaemia rates were higher for both IDegLira and IGlar U100 for the lowest baseline BMI category; however, hypoglycaemia rates were inversely proportional to BMI category with IGlar U100, a trend not seen with IDegLira. An explanation for this could be that patients with lower BMI tend to be more insulin sensitive and, therefore, may be more vulnerable to insulin&#x02010;induced hypoglycaemia.<xref rid="dom13043-bib-0015" ref-type="ref">15</xref>
</p><p>The interpretation of our analysis is limited by its <italic>post hoc</italic> nature and by the fact that patients with a very high HbA1c level (&#x0003e;10%) or BMI (&#x0003e;40&#x02009;kg/m<sup>2</sup>) were excluded from the trial. Nevertheless, the data are from a well&#x02010;conducted randomized controlled trial, with a large cohort of participants and large numbers of participants in most categories, allowing a meaningful analysis.</p><p>In conclusion, in the present study, IDegLira was efficacious across the categories of baseline HbA1c, FPG or BMI tested, confirming the findings of previous studies in patients with T2D uncontrolled on OADs or basal insulin with or without OADs.<xref rid="dom13043-bib-0011" ref-type="ref">11</xref> These results show that IDegLira treatment provides better glycaemic control, together with weight loss and lower proportions of patients experiencing hypoglycaemia, compared with basal insulin uptitration.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom13043-supitem-0001"><caption><p>Supplementary Appendix</p><p>
<bold>Table S1.</bold> Number of patients in each baseline characteristic category.</p><p>
<bold>Figure S1.</bold> Safety of <styled-content style="fixed-case">IDegLira</styled-content> versus <styled-content style="fixed-case">IGlar U</styled-content>100 in subjects stratified according to baseline <styled-content style="fixed-case">HbA</styled-content>
<sub>1c</sub>: <styled-content style="fixed-case">A</styled-content>, confirmed hypoglycaemia rate and <styled-content style="fixed-case">B</styled-content>, daily insulin dose.</p><p>
<bold>Figure S2.</bold> Safety of <styled-content style="fixed-case">IDegLira</styled-content> versus <styled-content style="fixed-case">IGlar U</styled-content>100 in subjects stratified according to baseline <styled-content style="fixed-case">FPG</styled-content>: <styled-content style="fixed-case">A</styled-content>, confirmed hypoglycaemia rate and <styled-content style="fixed-case">B</styled-content>, daily insulin dose.</p><p>
<bold>Figure S3.</bold> Safety of <styled-content style="fixed-case">IDegLira</styled-content> versus <styled-content style="fixed-case">IGlar U</styled-content>100 in subjects stratified according to baseline <styled-content style="fixed-case">BMI</styled-content>: <styled-content style="fixed-case">A</styled-content>, confirmed hypoglycaemia rate and <styled-content style="fixed-case">B</styled-content>, daily insulin dose.</p></caption><media xlink:href="DOM-20-200-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom13043-sec-0008"><title>ACKNOWLEDGEMENTS</title><p>The authors thank J. Langer and K. Begtrup (both of Novo Nordisk A/S) for their review and input to the manuscript. Medical writing assistance and editorial/submission support was provided by L. C. Brackenbury, A. Buss and C. Jones of Watermeadow Medical, Witney, UK, an Ashfield Company, part of UDG Healthcare plc, funded by Novo Nordisk A/S. Parts of this study have been presented as posters at the American Diabetes Association annual congress 2016 and the European Association for the Study of Diabetes annual congress 2016.</p><sec id="dom13043-sec-0009" sec-type="COI-statement"><title>Conflict of interest</title><p>I. L. has received research funding form Novo Nordisk, Pfizer, Merck, Novartis, GI Dynamics and has received publication support and/or other in&#x02010;kind services from Novo Nordisk, Boheringer Ingelheimer, Astra Zeneca and Sanofi. S. H. has received research support from Novo Nordisk, Sanofi, Merck, Abbott, Janssen and AstraZeneca, has served on an advisory panel for Novo Nordisk, Sanofi, Merck, AstraZeneca, Lilly/BI, Amgen, Abbott and Janssen, has served as a consultant for Novo Nordisk, Sanofi, Merck, Abbott, Janssen and AstraZeneca, and/or other in&#x02010;kind services for CIHR, CDA, and The Lawson Foundation. E. J. has served on advisory panels and/or speaker bureaus for Novo Nordisk, Lilly, AstraZeneca, Boehringer, MSD, Janssen, Roche and Novartis, is a board member for Novo Nordisk and Lilly, and has received research support from Novo Nordisk, Novartis, Gilead, Roche, Miltenyi Biotech, Biotest, Wacker Chemie, Fresenius, DFG, BMBF, EU, JDRF and VW&#x02010;Stiftung. K. C. is a Novo Nordisk employee. M. F. R. is a Novo Nordisk employee and shareholder. E. J. has received consultant fees from Amgen, AstraZeneca, Lilly, MSD and Novo Nordisk, has been a clinical investigator for AstraZeneca, Boehringer, GSK, Janssen, Lilly, MSD, Novo Nordisk and Pfizer, and has served on speaker bureaus for AstraZeneca, GSK, Lilly, MSD and Novo Nordisk.</p></sec><sec id="dom13043-sec-0010"><title>Author contributions</title><p>I. L., S. H., E. J. and E. J. were investigators on the DUAL V trial. All authors confirm that they meet the International Committee of Medical Journal Editors requirements for authorship and that they have contributed to the critical analysis and interpretation of the data, drafting/critically revising the manuscript and share in the final responsibility for the content of the manuscript and the decision to submit it for publication.</p></sec></ack><ref-list id="dom13043-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="dom13043-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom13043-cit-0002">
<collab collab-type="authors">American Diabetes Association</collab>
. <article-title>Standards of medical care in diabetes</article-title>. <source>Diabetes Care</source>. <year>2017</year>;<volume>40</volume>(<issue>Suppl 1</issue>):<fpage>S1</fpage>&#x02013;<lpage>S133</lpage>.<pub-id pub-id-type="pmid">27979885</pub-id></mixed-citation></ref><ref id="dom13043-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom13043-cit-0003">
<string-name>
<surname>Cantrell</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Alatorre</surname>
<given-names>CI</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>EJ</given-names>
</string-name>, et al. <article-title>A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity</article-title>. <source>Diabetes Obes Metab</source>. <year>2010</year>;<volume>12</volume>:<fpage>845</fpage>&#x02013;<lpage>857</lpage>.<pub-id pub-id-type="pmid">20920036</pub-id></mixed-citation></ref><ref id="dom13043-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom13043-cit-0004">
<string-name>
<surname>Bain</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Feher</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Russell&#x02010;Jones</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Khunti</surname>
<given-names>K</given-names>
</string-name>. <article-title>Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK</article-title>. <source>Diabetes Obes Metab</source>. <year>2016</year>;<volume>18</volume>:<fpage>1157</fpage>&#x02013;<lpage>1166</lpage>.<pub-id pub-id-type="pmid">27491724</pub-id></mixed-citation></ref><ref id="dom13043-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom13043-cit-0005">
<string-name>
<surname>Gough</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Bode</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Woo</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Efficacy and safety of a fixed&#x02010;ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open&#x02010;label, randomised, 26&#x02010;week, treat&#x02010;to&#x02010;target trial in insulin&#x02010;na&#x000ef;ve patients with type 2 diabetes</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2014</year>;<volume>2</volume>:<fpage>885</fpage>&#x02013;<lpage>893</lpage>.<pub-id pub-id-type="pmid">25190523</pub-id></mixed-citation></ref><ref id="dom13043-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom13043-cit-0006">
<string-name>
<surname>Gough</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Bode</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Woo</surname>
<given-names>VC</given-names>
</string-name>, et al. <article-title>One&#x02010;year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26&#x02010;week extension to a 26&#x02010;week main trial</article-title>. <source>Diabetes Obes Metab</source>. <year>2015</year>;<volume>17</volume>:<fpage>965</fpage>&#x02013;<lpage>973</lpage>.<pub-id pub-id-type="pmid">25980900</pub-id></mixed-citation></ref><ref id="dom13043-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom13043-cit-0007">
<string-name>
<surname>Rodbard</surname>
<given-names>HW</given-names>
</string-name>, <string-name>
<surname>Bode</surname>
<given-names>BW</given-names>
</string-name>, <string-name>
<surname>Harris</surname>
<given-names>SB</given-names>
</string-name>, et al. <article-title>Safety and efficacy of IDegLira added to sulphonylureas alone or sulphonylureas and metformin in insulin&#x02010;na&#x000ef;ve patients with type 2 diabetes: the DUAL IV trial</article-title>. <source>Diabet Med</source>. <year>2017</year>;<volume>34</volume>(<issue>2</issue>):<fpage>189</fpage>&#x02013;<lpage>196</lpage>.<pub-id pub-id-type="pmid">27589252</pub-id></mixed-citation></ref><ref id="dom13043-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom13043-cit-0008">
<string-name>
<surname>Harris</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kocsis</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Prager</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Safety and efficacy of IDegLira titrated once weekly vs twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial</article-title>. <source>Diabetes Obes Metab</source>. <year>2017</year>;<volume>19</volume>(<issue>6</issue>):<fpage>858</fpage>&#x02013;<lpage>865</lpage>.<pub-id pub-id-type="pmid">28124817</pub-id></mixed-citation></ref><ref id="dom13043-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom13043-cit-0009">
<string-name>
<surname>Linjawi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bode</surname>
<given-names>BW</given-names>
</string-name>, <string-name>
<surname>Chaykin</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP&#x02010;1 receptor agonist and oral therapy: DUAL III randomized clinical trial</article-title>. <source>Diabetes Ther</source>. <year>2017</year>;<volume>8</volume>(<issue>1</issue>):<fpage>101</fpage>&#x02013;<lpage>114</lpage>.<pub-id pub-id-type="pmid">27943107</pub-id></mixed-citation></ref><ref id="dom13043-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom13043-cit-0010">
<string-name>
<surname>Buse</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Vilsboll</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Thurman</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Contribution of liraglutide in the fixed&#x02010;ratio combination of insulin degludec and liraglutide (IDegLira)</article-title>. <source>Diabetes Care</source>. <year>2014</year>;<volume>37</volume>:<fpage>2926</fpage>&#x02013;<lpage>2933</lpage>.<pub-id pub-id-type="pmid">25114296</pub-id></mixed-citation></ref><ref id="dom13043-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom13043-cit-0011">
<string-name>
<surname>Lingvay</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>P&#x000e9;rez Manghi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Garc&#x000ed;a&#x02010;Hern&#x000e1;ndez</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Effect of insulin glargine up&#x02010;titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial</article-title>. <source>JAMA</source>. <year>2016</year>;<volume>315</volume>:<fpage>898</fpage>&#x02013;<lpage>907</lpage>.<pub-id pub-id-type="pmid">26934259</pub-id></mixed-citation></ref><ref id="dom13043-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom13043-cit-0012">
<string-name>
<surname>Rodbard</surname>
<given-names>HW</given-names>
</string-name>, <string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Woo</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Benefits of combination of insulin degludec and liraglutide (IDegLira) are independent of baseline HbA1c and duration of type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source>. <year>2016</year>;<volume>18</volume>:<fpage>40</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">26343931</pub-id></mixed-citation></ref><ref id="dom13043-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom13043-cit-0013">
<string-name>
<surname>Inzucchi</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Bergenstal</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name>, et al. <article-title>Management of hyperglycemia in type 2 diabetes, 2015: a patient&#x02010;centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes</article-title>. <source>Diabetes Care</source>. <year>2015</year>;<volume>38</volume>:<fpage>140</fpage>&#x02013;<lpage>149</lpage>.<pub-id pub-id-type="pmid">25538310</pub-id></mixed-citation></ref><ref id="dom13043-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom13043-cit-0014">
<string-name>
<surname>Eng</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kramer</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Zinman</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Retnakaran</surname>
<given-names>R</given-names>
</string-name>. <article-title>Glucagon&#x02010;like peptide&#x02010;1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta&#x02010;analysis</article-title>. <source>Lancet</source>. <year>2014</year>;<volume>384</volume>:<fpage>2228</fpage>&#x02013;<lpage>2234</lpage>.<pub-id pub-id-type="pmid">25220191</pub-id></mixed-citation></ref><ref id="dom13043-bib-0014"><label>14</label><mixed-citation publication-type="miscellaneous" id="dom13043-cit-0015">
<collab collab-type="authors">The National Institute for Health and Care Excellence (NICE)</collab>
. Type 2 diabetes in adults: management. <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/ng28">https://www.nice.org.uk/guidance/ng28</ext-link>. Accessed May 1, 2017.</mixed-citation></ref><ref id="dom13043-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom13043-cit-0016">
<collab collab-type="authors">ORIGIN Trial Investigators</collab>
. <article-title>Predictors of nonsevere and severe hypoglycemia during glucose&#x02010;lowering treatment with insulin glargine or standard drugs in the ORIGIN trial</article-title>. <source>Diabetes Care</source>. <year>2015</year>;<volume>38</volume>:<fpage>22</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">25352653</pub-id></mixed-citation></ref></ref-list></back></article>